Adam Shilling

Adam Shilling possesses extensive experience in regulatory affairs and drug development across several prominent pharmaceutical companies. Currently serving as the Chief Development Officer at Nanocan Therapeutics Corporation since September 2022, Adam leads strategy and execution for regulatory and clinical functions. As the President and Founder of AS Pharma Consulting, LLC since April 2022, Adam provides expert consulting services for drug development. Previous roles include Vice President of Early Development and Regulatory Affairs at Prelude Therapeutics Incorporated and Executive Director of Regulatory Affairs at Incyte Pharmaceuticals, where Adam defined global regulatory strategies and coordinated submissions for numerous programs. Adam's academic background includes a Ph.D. in Toxicology from Oregon State University and a B.S. in Marine Biology from Long Island University, Southampton Campus.